Three quarters of UK’s long Covid sufferers have had to cut back or change work they do: Survey


Share post:

More than three quarters of British people, who have suffered persistent ill health following a Covid-19 infection, have had to cut back or change the work they do, according to a survey on the impact of long Covid published on Wednesday (November 9).

In the survey of 1,002 people, conducted by market research company Censuswide, some 98 per cent of long Covid sufferers said the condition had limited their ability to work, with 78 per cent needing to cut back or change their work and 19 having ceased work altogether.

Long Covid, a collection of symptoms ranging from pain and heart palpitations to insomnia and brain fog, can last for many months after initial infection.

Britain’s most recent official labour market data showed that a record proportion of people classified as “economically inactive” – neither working nor looking for a job – were suffering from long-term sickness. In absolute terms, the number of working-age people who are long-term sick has risen by 378,000 since early 2020.

Bank of England officials have highlighted lengthy waits for routine treatment in Britain’s public healthcare system, as well as long Covid, as potential reasons for the rise, which limits the economy’s ability to grow without boosting inflation.

The Office for National Statistics estimates that 2.1 million people – 3.3 per cent of the population – were suffering from long Covid as of October 1, which it defined as symptoms that had lasted more than four weeks after a Covid-19 infection.

Of those, 73 per cent said long Covid was limiting their day-to-day activities, and 16 per cent – 333,000 people – said their activities had been significantly limited.

In the survey, 59 per cent of people diagnosed with long Covid said they felt more tired, 42 per cent felt physically weaker, 37 per cent found it harder to concentrate and 19 per cent were in pain when working.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...